Business Context and Reporting Period
Pediatrix Medical Group, Inc. is the nation's leading health care services company focused on physician services for newborn, maternal-fetal, and pediatric subspecialty care. The company operates a national network of approximately 914 affiliated physicians across 32 states and Puerto Rico, primarily staffing Neonatal Intensive Care Units (NICUs). This Form 10-K covers the fiscal year ended December 31, 2006.
Material Restatement: The filing includes a comprehensive restatement of financial statements for 2005, 2004, and prior periods due to an Audit Committee review of historical stock option grant practices. The review identified 56 grants (2.3 million shares) that were "backdated" between 1997 and 2000, and 584 additional grants (12.1 million shares) with erroneous measurement dates or accounting errors. No intentional misconduct by current executive officers was found, though process deficiencies and inadequate oversight were identified.
Key Financial Metrics (Year Ended Dec 31, 2006)
| Metric | 2006 (Restated) | 2005 (Restated) | Change |
|---|---|---|---|
| Net Patient Service Revenue | $818.6 million | $693.7 million | +18.0% |
| Net Income | $124.5 million | $87.5 million | +42.3% |
| Diluted EPS | $2.52 | $1.82 | +38.5% |
| Operating Margin | 24.3% | 21.0% | +3.3 pts |
| Cash and Equivalents | $69.6 million | $11.2 million | +521% |
| Working Capital | $80.3 million | ($13.0 million) | Improvement |
| Operating Cash Flow | $177.3 million | $162.4 million | +9.2% |
| Total Debt | $0.9 million | $1.5 million | -40% |
Note: 2005 results were significantly impacted by a $20.9 million liability reserve recorded for a government settlement. 2006 results reflect the adoption of FAS 123(R) for stock-based compensation, increasing expenses by approximately $8.3 million compared to the prior year.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased by $124.9 million, driven by $45.8 million from acquisitions (8 physician groups) and $79.1 million from same-unit growth. Same-unit growth was fueled by a new billing code improving reimbursement and a 3.6% increase in NICU patient days.
- Expense Management: General and administrative expenses decreased by $7.3 million (6.3%) primarily due to the absence of the $20.9 million government settlement reserve recorded in 2005. This decrease was partially offset by a $4.8 million increase in professional fees related to the stock option review and a $6.3 million increase in stock-based compensation.
- Profitability: Net income increased significantly, aided by the absence of the 2005 settlement charge and improved operating margins. The effective tax rate decreased to 38.16% in 2006 from 39.62% in 2005.
- Liquidity: Cash and cash equivalents surged from $11.2 million to $69.6 million, and working capital turned from a deficit of $13.0 million to a positive $80.3 million, driven by strong operating cash flows and proceeds from stock option exercises.
Guidance, Outlook, and Risks
- Outlook: Management plans to invest $50 million to $55 million in core business acquisitions during 2007. The company expects to continue evaluating opportunities in anesthesiology and other hospital-based specialties.
- Government Investigations: The company is subject to ongoing SEC and U.S. Attorney investigations regarding the stock option practices. While the Audit Committee found no evidence of intentional misconduct by current executives, the company faces potential litigation and regulatory proceedings. The company voluntarily contacted the SEC and is cooperating fully.
- Corporate Integrity Agreement: Following a $25.1 million settlement regarding Medicaid and TRICARE billing practices (1996-1999), the company is bound by a five-year Corporate Integrity Agreement with the Office of Inspector General (OIG), requiring strict compliance monitoring and reporting.
- Regulatory Risks: The company faces significant risks related to government reimbursement rates (primarily Medicaid), changes in health care legislation, and potential audits of billing practices. A shift in payor mix toward government programs could reduce average reimbursement rates.
Key Facts for Investor Verification
- Restatement Impact: Verify the specific adjustments made to prior years' financial statements due to the stock option review, particularly the impact on retained earnings and stock-based compensation expenses.
- Government Settlement: Confirm the status of the $25.1 million Medicaid/TRICARE settlement and the ongoing obligations under the Corporate Integrity Agreement.
- Stock Option Review: Monitor the outcome of the SEC and U.S. Attorney investigations into the backdating of stock options and any potential derivative lawsuits from shareholders.
- Payor Mix: Assess the concentration of revenue from government payors (26% of net revenue in 2006) and the risk of reimbursement rate reductions.
- Acquisition Strategy: Evaluate the integration of the eight physician groups acquired in 2006 and the planned $50-$55 million acquisition budget for 2007.